| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 13.2 | 7.6 |
| Profit before tax | -61.9 | -53.9 |
| Net income | -61.9 | -53.9 |
| EPS (diluted, $ a share) | $-0.30 | $-0.32 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +72.9% |
|---|
10-Q filed with the SEC, NASDAQ: WVE. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Wave Life Sciences, Inc.: key numbers
- Share price
- $2.87Close, Nov 16
- Market cap
- $566M
- Shares outstanding
- 197.23MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Wave Life Sciences, Inc.
All →Wave Life Sciences Financial Results
Wave Life Sciences reported Q3 2026 financial results, highlighting a cash position of $431 million and an expected runway into Q3 2028. The company is advancing its RNA editing and siRNA clinical programs, including planning for a registrational trial of WVE-006 in AATD and ongoing Phase 2a dosing for WVE-007 in obesity.
- Term
- Q3 2026
“Following positive FDA feedback, planning is underway for our potentially registrational trial of WVE-006 for AATD, which we believe offers an efficient path to potential full and accelerated approval, without the need for a separate confirmatory trial.”
Paul Bolno, MD, MBA, President and Chief Executive Officer
“Importantly, our PRISM platform and chemistry continue to demonstrate unique value both within our own pipeline and beyond. The advancement of a development candidate by GSK reflects the recognition of Wave’s differentiated technology, including our best-in-class siRNA with SpiNA design, with three additional collaboration programs still advancing.”
Paul Bolno, MD, MBA, President and Chief Executive Officer